Key highlights
- Overall survival was twice as long with Columvi and GemOx versus MabThera/Rituxan plus GemOx.
- Columvi and GemOx approved in over 50 countries.
- Three-year follow-up data from phase III STARGLO study released.
- Median follow-up was 35.1 months for R/R DLBCL patients.
Study Overview
Roche announced three-year follow-up data from the pivotal phase III STARGLO study, focusing on patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant (ASCT).
Key Findings
After a median follow-up of 35.1 months, overall survival for patients treated with Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) was twice as long compared to those treated with MabThera/Rituxan plus GemOx.
Global Approval
The Columvi and GemOx combination has been approved in more than 50 countries worldwide and is recommended in international treatment guidelines.
